nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP2B6—Thiotepa—urinary bladder cancer	0.11	0.184	CbGbCtD
Azelastine—ABCB1—Mitomycin—urinary bladder cancer	0.0743	0.124	CbGbCtD
Azelastine—CYP2A6—Fluorouracil—urinary bladder cancer	0.0548	0.0917	CbGbCtD
Azelastine—CYP3A4—Thiotepa—urinary bladder cancer	0.0337	0.0565	CbGbCtD
Azelastine—ADRA1B—vas deferens—urinary bladder cancer	0.0319	0.328	CbGeAlD
Azelastine—CYP2B6—Cisplatin—urinary bladder cancer	0.0303	0.0507	CbGbCtD
Azelastine—CYP2E1—Etoposide—urinary bladder cancer	0.0302	0.0505	CbGbCtD
Azelastine—CYP2C8—Fluorouracil—urinary bladder cancer	0.027	0.0452	CbGbCtD
Azelastine—CYP3A5—Etoposide—urinary bladder cancer	0.0235	0.0393	CbGbCtD
Azelastine—CYP2C8—Etoposide—urinary bladder cancer	0.0226	0.0377	CbGbCtD
Azelastine—ABCB1—Gemcitabine—urinary bladder cancer	0.0214	0.0358	CbGbCtD
Azelastine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0209	0.035	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0203	0.034	CbGbCtD
Azelastine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0188	0.0315	CbGbCtD
Azelastine—CYP1A2—Etoposide—urinary bladder cancer	0.0175	0.0292	CbGbCtD
Azelastine—CYP2C9—Cisplatin—urinary bladder cancer	0.016	0.0268	CbGbCtD
Azelastine—ABCB1—Cisplatin—urinary bladder cancer	0.0155	0.026	CbGbCtD
Azelastine—ABCB1—Etoposide—urinary bladder cancer	0.0153	0.0255	CbGbCtD
Azelastine—ABCB1—Doxorubicin—urinary bladder cancer	0.0104	0.0174	CbGbCtD
Azelastine—ABCB1—Methotrexate—urinary bladder cancer	0.0101	0.0169	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00981	0.0164	CbGbCtD
Azelastine—CYP3A4—Etoposide—urinary bladder cancer	0.00915	0.0153	CbGbCtD
Azelastine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00624	0.0104	CbGbCtD
Azelastine—CYP2C19—urine—urinary bladder cancer	0.00452	0.0464	CbGeAlD
Azelastine—CYP1A2—urine—urinary bladder cancer	0.00369	0.0379	CbGeAlD
Azelastine—CYP2C9—urine—urinary bladder cancer	0.0035	0.036	CbGeAlD
Azelastine—CYP2E1—urine—urinary bladder cancer	0.00332	0.0341	CbGeAlD
Azelastine—CYP3A4—urine—urinary bladder cancer	0.00267	0.0274	CbGeAlD
Azelastine—CYP2D6—urine—urinary bladder cancer	0.00263	0.027	CbGeAlD
Azelastine—CYP2A6—prostate gland—urinary bladder cancer	0.00252	0.0259	CbGeAlD
Azelastine—CYP2A6—seminal vesicle—urinary bladder cancer	0.00213	0.0219	CbGeAlD
Azelastine—ADRA1B—renal system—urinary bladder cancer	0.00194	0.02	CbGeAlD
Azelastine—KCNH2—prostate gland—urinary bladder cancer	0.00155	0.0159	CbGeAlD
Azelastine—KCNH2—seminal vesicle—urinary bladder cancer	0.00131	0.0134	CbGeAlD
Azelastine—CYP3A5—prostate gland—urinary bladder cancer	0.00128	0.0131	CbGeAlD
Azelastine—CYP2A6—vagina—urinary bladder cancer	0.00125	0.0128	CbGeAlD
Azelastine—HRH1—prostate gland—urinary bladder cancer	0.00124	0.0127	CbGeAlD
Azelastine—CYP2E1—prostate gland—urinary bladder cancer	0.00119	0.0122	CbGeAlD
Azelastine—KCNH2—renal system—urinary bladder cancer	0.00105	0.0108	CbGeAlD
Azelastine—KCNH2—urethra—urinary bladder cancer	0.00104	0.0106	CbGeAlD
Azelastine—CYP2E1—seminal vesicle—urinary bladder cancer	0.00101	0.0104	CbGeAlD
Azelastine—CYP2C8—renal system—urinary bladder cancer	0.000965	0.00991	CbGeAlD
Azelastine—CYP1A1—epithelium—urinary bladder cancer	0.00096	0.00986	CbGeAlD
Azelastine—HRH1—epithelium—urinary bladder cancer	0.000911	0.00936	CbGeAlD
Azelastine—CYP1A2—renal system—urinary bladder cancer	0.000903	0.00927	CbGeAlD
Azelastine—CYP1A1—renal system—urinary bladder cancer	0.000891	0.00915	CbGeAlD
Azelastine—HRH1—smooth muscle tissue—urinary bladder cancer	0.000878	0.00902	CbGeAlD
Azelastine—CYP1A1—urethra—urinary bladder cancer	0.000875	0.00899	CbGeAlD
Azelastine—CYP3A5—renal system—urinary bladder cancer	0.000871	0.00894	CbGeAlD
Azelastine—CYP2B6—renal system—urinary bladder cancer	0.000866	0.00889	CbGeAlD
Azelastine—KCNH2—female reproductive system—urinary bladder cancer	0.000845	0.00867	CbGeAlD
Azelastine—HRH1—urethra—urinary bladder cancer	0.00083	0.00853	CbGeAlD
Azelastine—CYP2E1—renal system—urinary bladder cancer	0.000812	0.00834	CbGeAlD
Azelastine—CYP2C19—vagina—urinary bladder cancer	0.000801	0.00822	CbGeAlD
Azelastine—CYP2E1—urethra—urinary bladder cancer	0.000798	0.00819	CbGeAlD
Azelastine—CYP2C8—female reproductive system—urinary bladder cancer	0.000773	0.00794	CbGeAlD
Azelastine—KCNH2—vagina—urinary bladder cancer	0.000764	0.00784	CbGeAlD
Azelastine—CYP1A1—female reproductive system—urinary bladder cancer	0.000713	0.00733	CbGeAlD
Azelastine—CYP2C8—vagina—urinary bladder cancer	0.000699	0.00718	CbGeAlD
Azelastine—CYP2B6—female reproductive system—urinary bladder cancer	0.000693	0.00712	CbGeAlD
Azelastine—CYP2C9—female reproductive system—urinary bladder cancer	0.000687	0.00705	CbGeAlD
Azelastine—ABCB1—prostate gland—urinary bladder cancer	0.000679	0.00697	CbGeAlD
Azelastine—HRH1—female reproductive system—urinary bladder cancer	0.000677	0.00695	CbGeAlD
Azelastine—CYP3A4—renal system—urinary bladder cancer	0.000654	0.00671	CbGeAlD
Azelastine—CYP2E1—female reproductive system—urinary bladder cancer	0.000651	0.00668	CbGeAlD
Azelastine—CYP1A1—vagina—urinary bladder cancer	0.000645	0.00663	CbGeAlD
Azelastine—CYP2D6—renal system—urinary bladder cancer	0.000643	0.0066	CbGeAlD
Azelastine—CYP3A5—vagina—urinary bladder cancer	0.000631	0.00648	CbGeAlD
Azelastine—CYP2B6—vagina—urinary bladder cancer	0.000627	0.00644	CbGeAlD
Azelastine—HRH1—vagina—urinary bladder cancer	0.000612	0.00629	CbGeAlD
Azelastine—ABCB1—seminal vesicle—urinary bladder cancer	0.000574	0.0059	CbGeAlD
Azelastine—CYP3A4—female reproductive system—urinary bladder cancer	0.000523	0.00538	CbGeAlD
Azelastine—CYP2D6—female reproductive system—urinary bladder cancer	0.000515	0.00529	CbGeAlD
Azelastine—ABCB1—epithelium—urinary bladder cancer	0.000499	0.00512	CbGeAlD
Azelastine—KCNH2—lymph node—urinary bladder cancer	0.000494	0.00507	CbGeAlD
Azelastine—ABCB1—renal system—urinary bladder cancer	0.000463	0.00475	CbGeAlD
Azelastine—ABCB1—urethra—urinary bladder cancer	0.000455	0.00467	CbGeAlD
Azelastine—CYP1A1—lymph node—urinary bladder cancer	0.000417	0.00429	CbGeAlD
Azelastine—HRH1—lymph node—urinary bladder cancer	0.000396	0.00407	CbGeAlD
Azelastine—ABCB1—female reproductive system—urinary bladder cancer	0.000371	0.00381	CbGeAlD
Azelastine—ABCB1—vagina—urinary bladder cancer	0.000335	0.00344	CbGeAlD
Azelastine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000287	0.00159	CcSEcCtD
Azelastine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000287	0.00159	CcSEcCtD
Azelastine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000285	0.00158	CcSEcCtD
Azelastine—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000284	0.00158	CcSEcCtD
Azelastine—Infection—Cisplatin—urinary bladder cancer	0.000283	0.00157	CcSEcCtD
Azelastine—Cough—Etoposide—urinary bladder cancer	0.000279	0.00154	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000278	0.00154	CcSEcCtD
Azelastine—Tachycardia—Cisplatin—urinary bladder cancer	0.000278	0.00154	CcSEcCtD
Azelastine—Hypertension—Etoposide—urinary bladder cancer	0.000276	0.00153	CcSEcCtD
Azelastine—Asthma—Methotrexate—urinary bladder cancer	0.000275	0.00152	CcSEcCtD
Azelastine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000274	0.00152	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000274	0.00152	CcSEcCtD
Azelastine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000272	0.00151	CcSEcCtD
Azelastine—Chest pain—Etoposide—urinary bladder cancer	0.000272	0.00151	CcSEcCtD
Azelastine—Somnolence—Gemcitabine—urinary bladder cancer	0.000272	0.0015	CcSEcCtD
Azelastine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00027	0.00149	CcSEcCtD
Azelastine—Discomfort—Etoposide—urinary bladder cancer	0.000269	0.00149	CcSEcCtD
Azelastine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000268	0.00148	CcSEcCtD
Azelastine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000267	0.00148	CcSEcCtD
Azelastine—Somnolence—Fluorouracil—urinary bladder cancer	0.000267	0.00148	CcSEcCtD
Azelastine—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000266	0.00147	CcSEcCtD
Azelastine—Face oedema—Doxorubicin—urinary bladder cancer	0.000266	0.00147	CcSEcCtD
Azelastine—Fatigue—Gemcitabine—urinary bladder cancer	0.000263	0.00146	CcSEcCtD
Azelastine—Confusional state—Etoposide—urinary bladder cancer	0.000263	0.00146	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000262	0.00145	CcSEcCtD
Azelastine—Pain—Gemcitabine—urinary bladder cancer	0.000261	0.00145	CcSEcCtD
Azelastine—Constipation—Gemcitabine—urinary bladder cancer	0.000261	0.00145	CcSEcCtD
Azelastine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000261	0.00144	CcSEcCtD
Azelastine—Asthenia—Thiotepa—urinary bladder cancer	0.00026	0.00144	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000259	0.00144	CcSEcCtD
Azelastine—Infection—Etoposide—urinary bladder cancer	0.000259	0.00144	CcSEcCtD
Azelastine—Asthma—Epirubicin—urinary bladder cancer	0.000257	0.00142	CcSEcCtD
Azelastine—Pruritus—Thiotepa—urinary bladder cancer	0.000257	0.00142	CcSEcCtD
Azelastine—Pain—Fluorouracil—urinary bladder cancer	0.000257	0.00142	CcSEcCtD
Azelastine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000256	0.00142	CcSEcCtD
Azelastine—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000255	0.00141	CcSEcCtD
Azelastine—Tachycardia—Etoposide—urinary bladder cancer	0.000255	0.00141	CcSEcCtD
Azelastine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000254	0.00141	CcSEcCtD
Azelastine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000252	0.00139	CcSEcCtD
Azelastine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000248	0.00138	CcSEcCtD
Azelastine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000247	0.00137	CcSEcCtD
Azelastine—Bronchitis—Epirubicin—urinary bladder cancer	0.000247	0.00137	CcSEcCtD
Azelastine—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000246	0.00136	CcSEcCtD
Azelastine—Pain—Cisplatin—urinary bladder cancer	0.000243	0.00135	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000243	0.00134	CcSEcCtD
Azelastine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000241	0.00134	CcSEcCtD
Azelastine—Dizziness—Thiotepa—urinary bladder cancer	0.00024	0.00133	CcSEcCtD
Azelastine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000239	0.00132	CcSEcCtD
Azelastine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000238	0.00132	CcSEcCtD
Azelastine—Asthma—Doxorubicin—urinary bladder cancer	0.000238	0.00132	CcSEcCtD
Azelastine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000237	0.00132	CcSEcCtD
Azelastine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000237	0.00131	CcSEcCtD
Azelastine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000235	0.0013	CcSEcCtD
Azelastine—Paraesthesia—Etoposide—urinary bladder cancer	0.000234	0.0013	CcSEcCtD
Azelastine—Weight increased—Epirubicin—urinary bladder cancer	0.000234	0.0013	CcSEcCtD
Azelastine—Haematuria—Methotrexate—urinary bladder cancer	0.000234	0.00129	CcSEcCtD
Azelastine—Dyspnoea—Etoposide—urinary bladder cancer	0.000233	0.00129	CcSEcCtD
Azelastine—Somnolence—Etoposide—urinary bladder cancer	0.000232	0.00128	CcSEcCtD
Azelastine—Epistaxis—Methotrexate—urinary bladder cancer	0.000231	0.00128	CcSEcCtD
Azelastine—Vomiting—Thiotepa—urinary bladder cancer	0.000231	0.00128	CcSEcCtD
Azelastine—Rash—Thiotepa—urinary bladder cancer	0.000229	0.00127	CcSEcCtD
Azelastine—Bronchitis—Doxorubicin—urinary bladder cancer	0.000229	0.00127	CcSEcCtD
Azelastine—Dermatitis—Thiotepa—urinary bladder cancer	0.000229	0.00127	CcSEcCtD
Azelastine—Headache—Thiotepa—urinary bladder cancer	0.000227	0.00126	CcSEcCtD
Azelastine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000225	0.00125	CcSEcCtD
Azelastine—Fatigue—Etoposide—urinary bladder cancer	0.000225	0.00125	CcSEcCtD
Azelastine—Pain—Etoposide—urinary bladder cancer	0.000223	0.00124	CcSEcCtD
Azelastine—Constipation—Etoposide—urinary bladder cancer	0.000223	0.00124	CcSEcCtD
Azelastine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000223	0.00123	CcSEcCtD
Azelastine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000221	0.00123	CcSEcCtD
Azelastine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000221	0.00122	CcSEcCtD
Azelastine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.00022	0.00122	CcSEcCtD
Azelastine—Asthenia—Gemcitabine—urinary bladder cancer	0.000219	0.00121	CcSEcCtD
Azelastine—Haematuria—Epirubicin—urinary bladder cancer	0.000219	0.00121	CcSEcCtD
Azelastine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000218	0.00121	CcSEcCtD
Azelastine—ABCB1—lymph node—urinary bladder cancer	0.000217	0.00223	CbGeAlD
Azelastine—Weight increased—Doxorubicin—urinary bladder cancer	0.000216	0.0012	CcSEcCtD
Azelastine—Epistaxis—Epirubicin—urinary bladder cancer	0.000216	0.0012	CcSEcCtD
Azelastine—Pruritus—Gemcitabine—urinary bladder cancer	0.000216	0.0012	CcSEcCtD
Azelastine—Nausea—Thiotepa—urinary bladder cancer	0.000216	0.00119	CcSEcCtD
Azelastine—Sinusitis—Epirubicin—urinary bladder cancer	0.000215	0.00119	CcSEcCtD
Azelastine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000215	0.00119	CcSEcCtD
Azelastine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000213	0.00118	CcSEcCtD
Azelastine—Pruritus—Fluorouracil—urinary bladder cancer	0.000212	0.00118	CcSEcCtD
Azelastine—Visual impairment—Methotrexate—urinary bladder cancer	0.000212	0.00117	CcSEcCtD
Azelastine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00021	0.00116	CcSEcCtD
Azelastine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000209	0.00116	CcSEcCtD
Azelastine—Rhinitis—Epirubicin—urinary bladder cancer	0.000206	0.00114	CcSEcCtD
Azelastine—Body temperature increased—Etoposide—urinary bladder cancer	0.000206	0.00114	CcSEcCtD
Azelastine—Abdominal pain—Etoposide—urinary bladder cancer	0.000206	0.00114	CcSEcCtD
Azelastine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000206	0.00114	CcSEcCtD
Azelastine—Eye disorder—Methotrexate—urinary bladder cancer	0.000205	0.00114	CcSEcCtD
Azelastine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000205	0.00114	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000205	0.00113	CcSEcCtD
Azelastine—Asthenia—Cisplatin—urinary bladder cancer	0.000204	0.00113	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000204	0.00113	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—urinary bladder cancer	0.000202	0.00112	CcSEcCtD
Azelastine—Epistaxis—Doxorubicin—urinary bladder cancer	0.0002	0.00111	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000199	0.0011	CcSEcCtD
Azelastine—Dizziness—Fluorouracil—urinary bladder cancer	0.000199	0.0011	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—urinary bladder cancer	0.000198	0.0011	CcSEcCtD
Azelastine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000195	0.00108	CcSEcCtD
Azelastine—Vomiting—Gemcitabine—urinary bladder cancer	0.000194	0.00108	CcSEcCtD
Azelastine—Rash—Gemcitabine—urinary bladder cancer	0.000193	0.00107	CcSEcCtD
Azelastine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000192	0.00107	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—urinary bladder cancer	0.000192	0.00107	CcSEcCtD
Azelastine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000192	0.00106	CcSEcCtD
Azelastine—Headache—Gemcitabine—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Azelastine—Flushing—Epirubicin—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Azelastine—Vomiting—Fluorouracil—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Azelastine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Azelastine—Rash—Fluorouracil—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Azelastine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Azelastine—Headache—Fluorouracil—urinary bladder cancer	0.000188	0.00104	CcSEcCtD
Azelastine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000187	0.00104	CcSEcCtD
Azelastine—Asthenia—Etoposide—urinary bladder cancer	0.000187	0.00104	CcSEcCtD
Azelastine—Back pain—Methotrexate—urinary bladder cancer	0.000185	0.00103	CcSEcCtD
Azelastine—Pruritus—Etoposide—urinary bladder cancer	0.000185	0.00102	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000183	0.00102	CcSEcCtD
Azelastine—Nausea—Gemcitabine—urinary bladder cancer	0.000181	0.001	CcSEcCtD
Azelastine—Vomiting—Cisplatin—urinary bladder cancer	0.000181	0.001	CcSEcCtD
Azelastine—Vision blurred—Methotrexate—urinary bladder cancer	0.00018	0.000999	CcSEcCtD
Azelastine—Rash—Cisplatin—urinary bladder cancer	0.000179	0.000994	CcSEcCtD
Azelastine—Dermatitis—Cisplatin—urinary bladder cancer	0.000179	0.000993	CcSEcCtD
Azelastine—Diarrhoea—Etoposide—urinary bladder cancer	0.000178	0.000988	CcSEcCtD
Azelastine—Nausea—Fluorouracil—urinary bladder cancer	0.000178	0.000988	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000178	0.000986	CcSEcCtD
Azelastine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000178	0.000984	CcSEcCtD
Azelastine—Flushing—Doxorubicin—urinary bladder cancer	0.000177	0.000979	CcSEcCtD
Azelastine—Tension—Epirubicin—urinary bladder cancer	0.000176	0.000974	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000175	0.000972	CcSEcCtD
Azelastine—Nervousness—Epirubicin—urinary bladder cancer	0.000174	0.000964	CcSEcCtD
Azelastine—Back pain—Epirubicin—urinary bladder cancer	0.000173	0.00096	CcSEcCtD
Azelastine—Malaise—Methotrexate—urinary bladder cancer	0.000173	0.000956	CcSEcCtD
Azelastine—Dizziness—Etoposide—urinary bladder cancer	0.000172	0.000955	CcSEcCtD
Azelastine—Vertigo—Methotrexate—urinary bladder cancer	0.000172	0.000953	CcSEcCtD
Azelastine—Nausea—Cisplatin—urinary bladder cancer	0.000169	0.000937	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—urinary bladder cancer	0.000169	0.000935	CcSEcCtD
Azelastine—Cough—Methotrexate—urinary bladder cancer	0.000167	0.000925	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000166	0.000921	CcSEcCtD
Azelastine—Vomiting—Etoposide—urinary bladder cancer	0.000166	0.000918	CcSEcCtD
Azelastine—Agitation—Epirubicin—urinary bladder cancer	0.000165	0.000912	CcSEcCtD
Azelastine—Rash—Etoposide—urinary bladder cancer	0.000164	0.000911	CcSEcCtD
Azelastine—Dermatitis—Etoposide—urinary bladder cancer	0.000164	0.00091	CcSEcCtD
Azelastine—Headache—Etoposide—urinary bladder cancer	0.000163	0.000905	CcSEcCtD
Azelastine—Myalgia—Methotrexate—urinary bladder cancer	0.000163	0.000903	CcSEcCtD
Azelastine—Chest pain—Methotrexate—urinary bladder cancer	0.000163	0.000903	CcSEcCtD
Azelastine—Tension—Doxorubicin—urinary bladder cancer	0.000163	0.000901	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000162	0.000899	CcSEcCtD
Azelastine—Malaise—Epirubicin—urinary bladder cancer	0.000162	0.000895	CcSEcCtD
Azelastine—Discomfort—Methotrexate—urinary bladder cancer	0.000161	0.000892	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—urinary bladder cancer	0.000161	0.000892	CcSEcCtD
Azelastine—Vertigo—Epirubicin—urinary bladder cancer	0.000161	0.000891	CcSEcCtD
Azelastine—Back pain—Doxorubicin—urinary bladder cancer	0.00016	0.000888	CcSEcCtD
Azelastine—Palpitations—Epirubicin—urinary bladder cancer	0.000158	0.000877	CcSEcCtD
Azelastine—Confusional state—Methotrexate—urinary bladder cancer	0.000158	0.000872	CcSEcCtD
Azelastine—Cough—Epirubicin—urinary bladder cancer	0.000156	0.000866	CcSEcCtD
Azelastine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000156	0.000865	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000156	0.000865	CcSEcCtD
Azelastine—Infection—Methotrexate—urinary bladder cancer	0.000155	0.00086	CcSEcCtD
Azelastine—Nausea—Etoposide—urinary bladder cancer	0.000155	0.000858	CcSEcCtD
Azelastine—Hypertension—Epirubicin—urinary bladder cancer	0.000155	0.000857	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000154	0.000852	CcSEcCtD
Azelastine—Myalgia—Epirubicin—urinary bladder cancer	0.000152	0.000845	CcSEcCtD
Azelastine—Chest pain—Epirubicin—urinary bladder cancer	0.000152	0.000845	CcSEcCtD
Azelastine—Agitation—Doxorubicin—urinary bladder cancer	0.000152	0.000844	CcSEcCtD
Azelastine—Anxiety—Epirubicin—urinary bladder cancer	0.000152	0.000842	CcSEcCtD
Azelastine—Discomfort—Epirubicin—urinary bladder cancer	0.000151	0.000835	CcSEcCtD
Azelastine—Malaise—Doxorubicin—urinary bladder cancer	0.000149	0.000828	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—urinary bladder cancer	0.000149	0.000826	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—urinary bladder cancer	0.000149	0.000825	CcSEcCtD
Azelastine—Confusional state—Epirubicin—urinary bladder cancer	0.000147	0.000816	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—urinary bladder cancer	0.000146	0.000811	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000146	0.00081	CcSEcCtD
Azelastine—Infection—Epirubicin—urinary bladder cancer	0.000145	0.000804	CcSEcCtD
Azelastine—Cough—Doxorubicin—urinary bladder cancer	0.000145	0.000801	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—urinary bladder cancer	0.000143	0.000793	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—urinary bladder cancer	0.000143	0.00079	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000142	0.000788	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—urinary bladder cancer	0.000141	0.000782	CcSEcCtD
Azelastine—Myalgia—Doxorubicin—urinary bladder cancer	0.000141	0.000782	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—urinary bladder cancer	0.000141	0.000779	CcSEcCtD
Azelastine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00014	0.000777	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—urinary bladder cancer	0.000139	0.000772	CcSEcCtD
Azelastine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000139	0.000771	CcSEcCtD
Azelastine—Somnolence—Methotrexate—urinary bladder cancer	0.000139	0.000769	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000138	0.000764	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—urinary bladder cancer	0.000136	0.000755	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000135	0.000749	CcSEcCtD
Azelastine—Fatigue—Methotrexate—urinary bladder cancer	0.000135	0.000746	CcSEcCtD
Azelastine—Infection—Doxorubicin—urinary bladder cancer	0.000134	0.000744	CcSEcCtD
Azelastine—Pain—Methotrexate—urinary bladder cancer	0.000134	0.00074	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000133	0.000738	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000132	0.000731	CcSEcCtD
Azelastine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000131	0.000727	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—urinary bladder cancer	0.00013	0.000722	CcSEcCtD
Azelastine—Somnolence—Epirubicin—urinary bladder cancer	0.00013	0.00072	CcSEcCtD
Azelastine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000129	0.000713	CcSEcCtD
Azelastine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000128	0.000708	CcSEcCtD
Azelastine—Fatigue—Epirubicin—urinary bladder cancer	0.000126	0.000698	CcSEcCtD
Azelastine—Pain—Epirubicin—urinary bladder cancer	0.000125	0.000692	CcSEcCtD
Azelastine—Constipation—Epirubicin—urinary bladder cancer	0.000125	0.000692	CcSEcCtD
Azelastine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000123	0.000684	CcSEcCtD
Azelastine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000123	0.000684	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000123	0.000683	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000121	0.000673	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000121	0.000668	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00012	0.000667	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—urinary bladder cancer	0.00012	0.000666	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00012	0.000662	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—urinary bladder cancer	0.000117	0.000646	CcSEcCtD
Azelastine—Pain—Doxorubicin—urinary bladder cancer	0.000116	0.000641	CcSEcCtD
Azelastine—Constipation—Doxorubicin—urinary bladder cancer	0.000116	0.000641	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000116	0.00064	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000116	0.00064	CcSEcCtD
Azelastine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000115	0.000638	CcSEcCtD
Azelastine—Asthenia—Methotrexate—urinary bladder cancer	0.000112	0.000621	CcSEcCtD
Azelastine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000111	0.000617	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000111	0.000613	CcSEcCtD
Azelastine—Pruritus—Methotrexate—urinary bladder cancer	0.000111	0.000612	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000108	0.000597	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000107	0.000592	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000107	0.000592	CcSEcCtD
Azelastine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000107	0.000592	CcSEcCtD
Azelastine—Asthenia—Epirubicin—urinary bladder cancer	0.000105	0.000581	CcSEcCtD
Azelastine—Pruritus—Epirubicin—urinary bladder cancer	0.000103	0.000573	CcSEcCtD
Azelastine—Dizziness—Methotrexate—urinary bladder cancer	0.000103	0.000572	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—urinary bladder cancer	0.0001	0.000554	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.97e-05	0.000552	CcSEcCtD
Azelastine—Vomiting—Methotrexate—urinary bladder cancer	9.93e-05	0.00055	CcSEcCtD
Azelastine—Rash—Methotrexate—urinary bladder cancer	9.85e-05	0.000546	CcSEcCtD
Azelastine—Dermatitis—Methotrexate—urinary bladder cancer	9.84e-05	0.000545	CcSEcCtD
Azelastine—Headache—Methotrexate—urinary bladder cancer	9.79e-05	0.000542	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—urinary bladder cancer	9.7e-05	0.000538	CcSEcCtD
Azelastine—Dizziness—Epirubicin—urinary bladder cancer	9.67e-05	0.000535	CcSEcCtD
Azelastine—Pruritus—Doxorubicin—urinary bladder cancer	9.57e-05	0.00053	CcSEcCtD
Azelastine—Vomiting—Epirubicin—urinary bladder cancer	9.29e-05	0.000515	CcSEcCtD
Azelastine—Nausea—Methotrexate—urinary bladder cancer	9.28e-05	0.000514	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—urinary bladder cancer	9.26e-05	0.000513	CcSEcCtD
Azelastine—Rash—Epirubicin—urinary bladder cancer	9.22e-05	0.000511	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—urinary bladder cancer	9.21e-05	0.00051	CcSEcCtD
Azelastine—Headache—Epirubicin—urinary bladder cancer	9.16e-05	0.000507	CcSEcCtD
Azelastine—Dizziness—Doxorubicin—urinary bladder cancer	8.94e-05	0.000495	CcSEcCtD
Azelastine—Nausea—Epirubicin—urinary bladder cancer	8.68e-05	0.000481	CcSEcCtD
Azelastine—Vomiting—Doxorubicin—urinary bladder cancer	8.6e-05	0.000476	CcSEcCtD
Azelastine—Rash—Doxorubicin—urinary bladder cancer	8.53e-05	0.000472	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—urinary bladder cancer	8.52e-05	0.000472	CcSEcCtD
Azelastine—Headache—Doxorubicin—urinary bladder cancer	8.47e-05	0.000469	CcSEcCtD
Azelastine—Nausea—Doxorubicin—urinary bladder cancer	8.03e-05	0.000445	CcSEcCtD
Azelastine—CYP2A6—Metabolism—GPX1—urinary bladder cancer	1.58e-05	0.000127	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.58e-05	0.000127	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—EGFR—urinary bladder cancer	1.58e-05	0.000127	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.56e-05	0.000125	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.56e-05	0.000125	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	1.55e-05	0.000125	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.54e-05	0.000124	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—RHOA—urinary bladder cancer	1.52e-05	0.000122	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.51e-05	0.000122	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.5e-05	0.00012	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.5e-05	0.00012	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—KRAS—urinary bladder cancer	1.49e-05	0.00012	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.49e-05	0.000119	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.49e-05	0.000119	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.48e-05	0.000119	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.47e-05	0.000118	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.47e-05	0.000118	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	1.46e-05	0.000117	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.45e-05	0.000117	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.45e-05	0.000116	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—S100B—urinary bladder cancer	1.45e-05	0.000116	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.44e-05	0.000116	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	0.000116	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NCOR1—urinary bladder cancer	1.44e-05	0.000116	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.43e-05	0.000115	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	1.42e-05	0.000114	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.42e-05	0.000114	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.42e-05	0.000114	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—IL2—urinary bladder cancer	1.4e-05	0.000113	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	1.37e-05	0.00011	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.37e-05	0.00011	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.36e-05	0.000109	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.36e-05	0.000109	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.35e-05	0.000108	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	1.34e-05	0.000108	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CXCL8—urinary bladder cancer	1.33e-05	0.000107	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.33e-05	0.000107	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.33e-05	0.000107	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.33e-05	0.000107	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TP53—urinary bladder cancer	1.32e-05	0.000106	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.32e-05	0.000106	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.32e-05	0.000106	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.31e-05	0.000105	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	0.000105	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	0.000105	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	1.3e-05	0.000105	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.3e-05	0.000105	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.3e-05	0.000105	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.3e-05	0.000104	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.28e-05	0.000103	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.28e-05	0.000102	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.27e-05	0.000102	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL2—urinary bladder cancer	1.27e-05	0.000102	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.27e-05	0.000102	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.27e-05	0.000102	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	1.27e-05	0.000102	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TERT—urinary bladder cancer	1.27e-05	0.000102	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—HRAS—urinary bladder cancer	1.27e-05	0.000102	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.26e-05	0.000101	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.25e-05	0.000101	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.25e-05	0.0001	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.25e-05	0.0001	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.25e-05	0.0001	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—TYMS—urinary bladder cancer	1.24e-05	0.0001	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.23e-05	9.89e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	9.88e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	9.88e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.23e-05	9.86e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	9.85e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.23e-05	9.84e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.22e-05	9.83e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.21e-05	9.74e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.21e-05	9.7e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.21e-05	9.69e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.2e-05	9.62e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.19e-05	9.54e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PPARG—urinary bladder cancer	1.18e-05	9.5e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—GPX1—urinary bladder cancer	1.18e-05	9.46e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.18e-05	9.46e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	1.16e-05	9.35e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.16e-05	9.33e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	1.16e-05	9.29e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.15e-05	9.26e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	1.15e-05	9.26e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.15e-05	9.24e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TERT—urinary bladder cancer	1.15e-05	9.22e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.14e-05	9.16e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	1.14e-05	9.13e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	1.13e-05	9.08e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.13e-05	9.06e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.13e-05	9.06e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.11e-05	8.93e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.1e-05	8.8e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	1.09e-05	8.73e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.08e-05	8.67e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.07e-05	8.59e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.06e-05	8.52e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.06e-05	8.51e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.06e-05	8.5e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	1.05e-05	8.46e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	1.02e-05	8.22e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.02e-05	8.22e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.02e-05	8.18e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.01e-05	8.14e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.01e-05	8.09e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.01e-05	8.09e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.01e-05	8.09e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.99e-06	8.02e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	9.97e-06	8.01e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—TYMS—urinary bladder cancer	9.94e-06	7.98e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.93e-06	7.97e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	9.91e-06	7.96e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.83e-06	7.89e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.83e-06	7.89e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.8e-06	7.87e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.8e-06	7.87e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	9.79e-06	7.86e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	9.74e-06	7.82e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.67e-06	7.76e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	9.64e-06	7.74e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	9.55e-06	7.67e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.51e-06	7.63e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	9.47e-06	7.6e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.41e-06	7.56e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	9.37e-06	7.52e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PPARG—urinary bladder cancer	9.35e-06	7.51e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PPARG—urinary bladder cancer	9.33e-06	7.49e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	9.31e-06	7.48e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	9.29e-06	7.46e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	9.26e-06	7.44e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	9.26e-06	7.44e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.24e-06	7.42e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	9.2e-06	7.39e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	9.18e-06	7.37e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	9.18e-06	7.37e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	9.17e-06	7.37e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	8.99e-06	7.21e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	8.97e-06	7.21e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	8.97e-06	7.2e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	8.97e-06	7.2e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	8.9e-06	7.15e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.87e-06	7.12e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	8.86e-06	7.12e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPARG—urinary bladder cancer	8.82e-06	7.08e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	8.82e-06	7.08e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.79e-06	7.06e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.71e-06	6.99e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.69e-06	6.97e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.66e-06	6.95e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8.63e-06	6.93e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	8.54e-06	6.86e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	8.47e-06	6.8e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	8.33e-06	6.69e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	8.3e-06	6.67e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.26e-06	6.63e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	8.19e-06	6.57e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTEN—urinary bladder cancer	8.12e-06	6.52e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	8.12e-06	6.52e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	8.11e-06	6.52e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	8.08e-06	6.49e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.94e-06	6.37e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.9e-06	6.34e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	7.87e-06	6.32e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.85e-06	6.3e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.85e-06	6.3e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	7.82e-06	6.28e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	7.77e-06	6.24e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—EP300—urinary bladder cancer	7.74e-06	6.22e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	7.52e-06	6.04e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	7.52e-06	6.03e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.51e-06	6.03e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	7.51e-06	6.03e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	7.38e-06	5.92e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	7.36e-06	5.91e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7.34e-06	5.9e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	7.34e-06	5.89e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	7.22e-06	5.79e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	7.13e-06	5.72e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	7.12e-06	5.72e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	7.1e-06	5.7e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	7.08e-06	5.69e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	7.08e-06	5.68e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.04e-06	5.66e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	6.94e-06	5.57e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.93e-06	5.57e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	6.93e-06	5.57e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	6.81e-06	5.47e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.77e-06	5.43e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	6.75e-06	5.42e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	6.64e-06	5.33e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.64e-06	5.33e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.59e-06	5.29e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.58e-06	5.28e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	6.57e-06	5.27e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	6.55e-06	5.26e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	6.45e-06	5.18e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.42e-06	5.16e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	6.42e-06	5.15e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	6.41e-06	5.15e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.4e-06	5.14e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.38e-06	5.12e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	6.36e-06	5.11e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.32e-06	5.08e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—EP300—urinary bladder cancer	6.25e-06	5.02e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.13e-06	4.92e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—EP300—urinary bladder cancer	6.12e-06	4.91e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	6.11e-06	4.91e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—EP300—urinary bladder cancer	6.11e-06	4.9e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.06e-06	4.86e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.06e-06	4.86e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTEN—urinary bladder cancer	6.05e-06	4.86e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	5.94e-06	4.77e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	5.88e-06	4.72e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.8e-06	4.66e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—EP300—urinary bladder cancer	5.77e-06	4.63e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	5.75e-06	4.62e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.69e-06	4.57e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.68e-06	4.56e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.62e-06	4.51e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.55e-06	4.45e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.54e-06	4.45e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	5.44e-06	4.37e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.4e-06	4.34e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.35e-06	4.3e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	5.33e-06	4.28e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—EP300—urinary bladder cancer	5.29e-06	4.25e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.22e-06	4.19e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	5.21e-06	4.18e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.18e-06	4.16e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.95e-06	3.98e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	4.92e-06	3.95e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.83e-06	3.88e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	4.83e-06	3.88e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.72e-06	3.79e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	4.62e-06	3.71e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.61e-06	3.7e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.55e-06	3.66e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.51e-06	3.62e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.42e-06	3.55e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	4.37e-06	3.51e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.34e-06	3.49e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.34e-06	3.48e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.3e-06	3.46e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	4.18e-06	3.36e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.17e-06	3.35e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.86e-06	3.1e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.68e-06	2.95e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.41e-06	2.74e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.98e-06	2.39e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.84e-06	2.28e-05	CbGpPWpGaD
